Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-05-04 AGM Information
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
AGM - change to proposed amendments to Telix Constitution 3 pages 217.7KB
AGM Information Classification · 95% confidence The document is an ASX release from Telix Pharmaceuticals Limited dated 5 May 2022. It discusses changes to the proposed amendments to the Telix Constitution related to virtual meetings for the Annual General Meeting (AGM). The content focuses on governance matters, specifically amendments to the company's constitution and rules for shareholder meetings. There is no financial data, earnings information, or detailed report content. The document is an announcement related to the AGM and governance changes, not the AGM materials themselves or the full annual report. Therefore, the document fits best under AGM Information (AGM-R) as it relates to the Annual General Meeting and changes to meeting procedures.
2022-05-04 English
Appendix 3Y - Change in Directors Interests - O Buck 2 pages 80.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is concise and focused solely on this transaction, with no financial statements or broader company information. Therefore, it fits the 'Director's Dealing' category (DIRS).
2022-04-27 English
Appendix 4C and Activities Report for March 2022 quarter 13 pages 1.4MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX release titled 'Activities Report and Appendix 4C for March 2022 Quarter' from Telix Pharmaceuticals Limited. It includes detailed financial data such as cash reserves, operating outflows, capital raising activities, and cash runway. It also provides a comprehensive activities report covering commercial launches, clinical trial progress, regulatory approvals, and distribution agreements. The document contains substantive financial data and analysis for the quarter ended 31 March 2022, including an Appendix 4C cash flow statement, which is a quarterly report format used in Australia. The length and content indicate it is a comprehensive quarterly report rather than a brief announcement or presentation. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-21 English
2022 AGM Notice of Meeting, Proxy Form and Online Guide 40 pages 2.1MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting Explanatory Memorandum' and includes details about the date, time, and location of the AGM, instructions for shareholders on how to attend (including virtual attendance), and the business to be conducted at the meeting. It contains resolutions to be voted on, including adoption of the remuneration report, election and re-election of directors, approval of equity incentive plans, and amendments to the constitution. The document also includes voting instructions, voting exclusion statements under the Corporations Act and ASX Listing Rules, and proxy information. There is no detailed financial data or full financial statements included, but rather information and materials related to the AGM itself. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. The document is not an Annual Report (10-K), Remuneration Information (DEF 14A), or a Declaration of Voting Results (DVA), but rather the notice and explanatory memorandum for the AGM.
2022-04-13 English
Securities Dealing Policy - adopted 11 April 2022 8 pages 142.2KB
Governance Information Classification · 95% confidence The document is a detailed policy titled 'Securities Dealing Policy' adopted by the Board of Telix Pharmaceuticals Limited. It outlines rules and procedures regarding insider trading, securities dealing restrictions, blackout periods, and responsibilities of directors, officers, and employees. It does not contain financial statements, earnings data, or regulatory announcements. Instead, it is a governance document related to internal rules on securities dealing and compliance with insider trading laws. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2022-04-13 English
ProstACT TARGET Phase II Study Ethics Approval 3 pages 253.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing the ethics approval for a Phase II clinical trial (ProstACT TARGET study) by Telix Pharmaceuticals Limited. It provides detailed information about the study design, objectives, and strategic importance, but it is not a financial report or earnings release. It is a corporate announcement related to clinical trial progress and regulatory approval for the study. There is no financial data, no mention of board changes, no voting results, no audit information, and no investor presentation format. The document is a regulatory announcement about a clinical trial milestone, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-04-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.